Recombinant Human GLIS3 Protein: Handling & Usage Protocol

Recombinant Human GLIS3 Protein is a zinc-finger transcription factor critical for pancreatic beta-cell development and thyroid organogenesis, now available from Aladdin Scientific (SKU: rp366987) for use in functional assays, protein interaction studies, and disease-mechanism research.

Product Name

Recombinant Human GLIS3 Protein

SKU

rp366987

Protein Family

GLIS family zinc-finger transcription factors (Krüppel-like)

Biological Role

Regulates pancreatic beta-cell development, insulin gene expression, and thyroid organogenesis

Recommended Storage

-80°C for long-term; avoid repeated freeze-thaw cycles

Typical Applications

EMSA, co-immunoprecipitation, reporter gene assays, protein-protein interaction studies

Introduction to GLIS3 and Its Research Significance

GLIS3 (GLI-Similar 3) is a member of the GLIS subfamily of Krüppel-like zinc-finger transcription factors. It plays indispensable roles in the differentiation and maintenance of pancreatic beta cells, regulation of insulin gene transcription, and development of the thyroid gland and kidney tubules. Loss-of-function mutations in GLIS3 are associated with a rare syndromic form of neonatal diabetes mellitus combined with congenital hypothyroidism, and genome-wide association studies (GWAS) have linked GLIS3 variants to risk of both type 1 and type 2 diabetes.

Recombinant Human GLIS3 Protein (rp366987) enables researchers to investigate these pathways in vitro, providing a defined, biologically relevant tool for mechanistic and translational studies. This protocol outlines the steps required to reconstitute, store, quality-verify, and experimentally apply this recombinant protein safely and reproducibly.

Materials and Equipment Required

Before beginning, ensure the following materials are available:

• Recombinant Human GLIS3 Protein (Aladdin Scientific, SKU: rp366987)
• Sterile, nuclease-free, protein-grade water or the recommended reconstitution buffer (typically PBS pH 7.4 with a carrier protein such as 0.1% BSA, unless otherwise specified in the Certificate of Analysis)
• Low-binding microcentrifuge tubes (1.5 mL)
• Calibrated micropipettes and sterile filtered tips
• Refrigerated microcentrifuge
• Dry ice or liquid nitrogen for snap-freezing aliquots
• –80°C freezer for long-term storage
• Protein quantification reagents (e.g., BCA or Bradford assay kit)
• SDS-PAGE and western blot reagents for identity verification
• Application-specific reagents (e.g., EMSA kit, co-IP lysis buffer, luciferase reporter assay system)

Always consult the Certificate of Analysis (CoA) supplied with the specific lot for exact formulation details, concentration, and purity data before proceeding.

Step-by-Step Reconstitution and Storage Protocol

Step 1 – Thawing: Transfer the vial from –80°C storage to ice. Allow it to thaw slowly on ice (10–15 min). Do not thaw at room temperature or in a water bath, as rapid temperature changes may denature the protein.

Step 2 – Brief centrifugation: Centrifuge the vial at 500–1,000 × g for 30 seconds to collect any lyophilized material or condensation from the cap. This step also applies to liquid-format preparations.

Step 3 – Reconstitution (lyophilized format): Add the volume of sterile reconstitution buffer specified in the CoA slowly along the side of the vial. Gently swirl or pipette to mix. Do NOT vortex. Allow 10 minutes at room temperature for complete dissolution.

Step 4 – Aliquoting: Divide the reconstituted protein into single-use aliquots in low-binding microcentrifuge tubes to minimize freeze-thaw cycles. Label each aliquot with protein name, lot number, concentration, date, and initials.

Step 5 – Storage: Store working aliquots at –80°C. Short-term storage (≤1 week) may be at 4°C if repeated access is required, but activity should be monitored. Avoid repeated freeze-thaw cycles (limit to ≤3 cycles maximum).

Step 6 – Carrier protein addition: If the supplied formulation does not already contain a stabilizing carrier protein, consider supplementing with 0.1% (w/v) BSA (IgG-free, protease-free) to improve stability during long-term storage.

Quality Verification and Experimental Applications

Quality Verification: Before committing the protein to key experiments, verify identity and purity as follows:

• SDS-PAGE: Run 1–2 µg under reducing and non-reducing conditions. The apparent molecular weight should be consistent with the predicted size of GLIS3 (refer to the CoA for the expected band position, as recombinant tags alter apparent MW).
• Western Blot: Confirm identity using a validated anti-GLIS3 or anti-tag antibody.
• Protein Quantification: Measure absorbance at A280 or use a BCA/Bradford assay to confirm working concentration.

Recommended Experimental Applications:

• Electrophoretic Mobility Shift Assay (EMSA): Use to confirm GLIS3 binding to its consensus DNA response elements (GLIS-binding sites). Titrate protein concentration from 10–500 nM to determine Kd.
• Co-Immunoprecipitation (Co-IP): Include GLIS3 as bait or prey to map protein-protein interactions relevant to insulin promoter regulation or Hedgehog pathway cross-talk.
• Reporter Gene Assay: Transfect GLIS3-responsive luciferase constructs into relevant cell lines (e.g., MIN6, INS-1) and supplement with recombinant GLIS3 protein via cell-penetrating strategies or use as a positive control in cell-free transcription systems.
• Structural Studies: Use in crystallography or cryo-EM studies of zinc-finger domain–DNA complexes.

Optimize protein concentrations empirically for each assay system; starting ranges are provided as general guidance only.

Troubleshooting Common Issues

The table below summarizes frequently encountered problems and recommended corrective actions when working with Recombinant Human GLIS3 Protein:

• Problem: Protein precipitation after reconstitution. Possible cause: Reconstitution buffer incompatibility or protein aggregation. Solution: Centrifuge at 10,000 × g for 5 min at 4°C to remove aggregates; adjust buffer composition (add NaCl to 150 mM or include 5% glycerol); ensure reconstitution was performed on ice or at 4°C.
• Problem: No detectable band on SDS-PAGE. Possible cause: Concentration too low or improper loading. Solution: Verify concentration by BCA assay; increase loading to 2–5 µg; ensure proper gel percentage (10–12% recommended for GLIS3).
• Problem: Loss of DNA-binding activity in EMSA. Possible cause: Protein denaturation due to excess freeze-thaw cycles or improper storage. Solution: Use freshly thawed aliquot; supplement binding buffer with DTT (1 mM) and ZnCl₂ (10 µM) to maintain zinc-finger integrity; confirm protein identity by western blot.
• Problem: High background in reporter assays. Possible cause: Endogenous GLIS pathway activity in the cell line used. Solution: Use a cell line with low endogenous GLIS3 expression; include appropriate negative controls (empty vector, heat-inactivated protein).
• Problem: Inconsistent results between experiments. Possible cause: Variability in protein concentration or activity between aliquots. Solution: Always quantify protein concentration fresh before each experiment; use the same lot number within a study where possible.

Frequently asked questions

What is the recommended reconstitution buffer for Recombinant Human GLIS3 Protein?

The specific reconstitution buffer and volume are stated on the Certificate of Analysis (CoA) supplied with each lot of rp366987. In general, sterile PBS (pH 7.4) supplemented with 0.1% BSA (carrier-protein grade) is suitable for most recombinant zinc-finger proteins; however, always defer to the lot-specific CoA instructions to ensure optimal activity and stability.

How many freeze-thaw cycles can Recombinant Human GLIS3 Protein tolerate?

As with most recombinant transcription factor proteins, repeated freeze-thaw cycles progressively reduce activity and increase aggregation risk. It is strongly recommended to limit freeze-thaw cycles to a maximum of three and to aliquot the protein into single-use volumes upon first thaw to preserve full biological activity across experiments.

What downstream assays is Recombinant Human GLIS3 Protein validated for?

Recombinant Human GLIS3 Protein (rp366987) is suitable for applications including electrophoretic mobility shift assay (EMSA) for DNA-binding studies, co-immunoprecipitation for protein interaction mapping, luciferase reporter gene assays, and structural biology approaches such as X-ray crystallography. Researchers should validate the protein in their specific assay system and consult the CoA for lot-specific activity data.

How should I confirm the identity and purity of the protein before use?

Run an SDS-PAGE gel with 1–2 µg of the reconstituted protein under reducing conditions and compare the apparent band size with the value stated on the CoA. Follow with western blot using a validated anti-GLIS3 or anti-tag antibody to confirm identity. Perform a BCA or Bradford assay to verify the working concentration independently of the supplied nominal concentration.

Is Recombinant Human GLIS3 Protein suitable for in vivo animal studies?

This product is intended for research use only (RUO) and is not validated or approved for in vivo therapeutic, diagnostic, or clinical applications. For in vitro mechanistic and biochemical studies it provides a well-defined research tool. Any intended in vivo use would require additional safety, sterility, and endotoxin testing beyond standard research specifications.

References

1. Senée V, et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nature Genetics, 2006.
2. Kang HS, et al. Transcription factor Glis3, a novel critical player in the regulation of pancreatic beta-cell development and insulin gene expression. Molecular and Cellular Biology, 2009.
3. Aylward A, et al. Shared cis-regulatory variants are associated with both type 1 and type 2 diabetes risk at the GLIS3 locus. Diabetes, 2018.
4. Aladdin Scientific. Recombinant Human GLIS3 Protein (rp366987) Product Datasheet. Aladdin Scientific.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.